C12N 2740/15045
Special targeting system for viral vectors
C12N2740/15045 (Special targeting system for viral vectors) appears on 72 US grants and 134 published applications in this corpus.
Search patents in C12N- Granted patents
- 72
- Published applications
- 134
- Assignees
- 83
- Inventors
- 231
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 4 |
| 2004 | 1 | 5 |
| 2005 | 0 | 6 |
| 2006 | 1 | 9 |
| 2007 | 1 | 1 |
| 2008 | 2 | 5 |
| 2009 | 3 | 6 |
| 2010 | 2 | 7 |
| 2011 | 3 | 1 |
| 2012 | 5 | 1 |
| 2013 | 3 | 5 |
| 2014 | 4 | 4 |
| 2015 | 4 | 9 |
| 2016 | 6 | 7 |
| 2017 | 5 | 5 |
| 2018 | 5 | 6 |
| 2019 | 5 | 6 |
| 2020 | 2 | 5 |
| 2021 | 3 | 2 |
| 2022 | 1 | 5 |
| 2023 | 3 | 2 |
| 2024 | 3 | 11 |
| 2025 | 2 | 12 |
| 2026 | 4 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Vectors and compositions for treating hemoglobinopathies11 Aug 2026US 12,703,864 B2Children's Medical Center Corporation
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,622 B2Massachusetts Institute of Technology
- Promoter specific for non-pigmented ciliary epithelial cells28 Apr 2026US 12,611,469 B2The Board of Trustees of the Leland Stanford Junior University
- Ligand discovery and gene delivery via retroviral surface display28 Oct 2025US 12,455,280 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display8 Oct 2026US 2026/0309700 A1Massachusetts Institute of Technology
- Universal protein g fusogens and adapter systems thereof and related lipid particles and uses24 Sep 2026US 2026/0286388 A1Sana Biotechnology, Inc.
- Mutant vsvg and targeting vector13 Aug 2026US 2026/0234198 A1Shenzhen Genocury Biotech Co., Ltd.
- Pharmaceutical compositions viral particles and methods of using the same13 Aug 2026US 2026/0234664 A1Interius Biotherapeutics, Inc.
- Viral vectors with engineered function and methods of production thereof23 Jul 2026US 2026/0207771 A1Lilium Therapeutics Inc.
Most cited
By later US patents
- Mammalian cell expressing Volvox carteri light-activated ion channel protein (VChR1)84US 8,815,582 B2The Board of Trustees of the Leland Stanford Junior University · 2014
- Systems, methods and compositions for optical stimulation of target cells76US 8,603,790 B2The Board of Trustees of the Leland Stanford Junior University · 2013
- Expression vector comprising a nucleotide sequence encoding a Volvox carteri light-activated ion channel protein (VChR1) and implantable device thereof49US 9,249,200 B2The Board of Trustees of the Leland Stanford Junior University · 2016
- Methods for treating parkinson's disease by optically stimulating target cells40US 9,394,347 B2The Board of Trustees of the Leland Stanford Junior University · 2016
- Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity24US 7,510,706 B2DNAVEC Research Inc. · 2009